Exicure (XCUR) Short term Debt (2016 - 2024)

Exicure (XCUR) reported Short term Debt of $1.0 million for Q2 2024, down 85.45% quarter-over-quarter from $6.9 million in Q4 2021.

Exicure (XCUR) Short term Debt (2016 - 2024) Analysis & Trends

Exicure has reported Short term Debt for 5 years, with the latest figure at $1.0 million in Q2 2024.

For the quarter ending Q2 2024, Short term Debt changed N/A year-over-year to $1.0 million; the trailing twelve-month figure through Jun 2024 stood at $1.0 million (changed N/A YoY), and the FY2021 full-year result was $6.9 million, changed N/A from the prior year.
Short term Debt for Q2 2024 stood at $1.0 million, down from $6.9 million in the prior quarter.
The five-year high for Short term Debt was $6.9 million in Q4 2021, with the low at $1.0 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn
9	Abivax	94.37 Bn	94.37 Bn	-
10	Exicure	19.38 Mn	16.77 Mn	-

Download Data